Cidara Therapeutics Inc (CDTX)
14.48
+0.58
(+4.17%)
USD |
NASDAQ |
Nov 14, 16:00
14.66
+0.18
(+1.24%)
After-Hours: 20:00
Cidara Therapeutics Cash and Short Term Investments (Quarterly): 127.39M for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 127.39M |
| June 30, 2024 | 164.37M |
| March 31, 2024 | 29.02M |
| December 31, 2023 | 35.78M |
| September 30, 2023 | 48.67M |
| June 30, 2023 | 50.43M |
| March 31, 2023 | 47.98M |
| December 31, 2022 | 32.73M |
| September 30, 2022 | 53.08M |
| June 30, 2022 | 24.64M |
| March 31, 2022 | 36.49M |
| December 31, 2021 | 59.68M |
| September 30, 2021 | 36.60M |
| June 30, 2021 | 48.28M |
| March 31, 2021 | 42.86M |
| December 31, 2020 | 35.91M |
| September 30, 2020 | 45.52M |
| June 30, 2020 | 54.83M |
| March 31, 2020 | 64.31M |
| December 31, 2019 | 50.27M |
| Date | Value |
|---|---|
| September 30, 2019 | 73.82M |
| June 30, 2019 | 44.57M |
| March 31, 2019 | 57.41M |
| December 31, 2018 | 74.56M |
| September 30, 2018 | 88.27M |
| June 30, 2018 | 103.20M |
| March 31, 2018 | 66.19M |
| December 31, 2017 | 75.31M |
| September 30, 2017 | 64.15M |
| June 30, 2017 | 78.01M |
| March 31, 2017 | 90.09M |
| December 31, 2016 | 104.62M |
| September 30, 2016 | 79.31M |
| June 30, 2016 | 87.09M |
| March 31, 2016 | 96.66M |
| December 31, 2015 | 107.51M |
| September 30, 2015 | 114.42M |
| June 30, 2015 | 122.30M |
| March 31, 2015 | 58.12M |
| December 31, 2014 | 22.80M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
24.64M
Minimum
Jun 2022
164.37M
Maximum
Jun 2024
54.44M
Average
48.13M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 930.44M |
| Arbutus Biopharma Corp | 127.79M |
| GlycoMimetics Inc | 22.39M |
| FibroGen Inc | 140.71M |
| Cue Biopharma Inc | 30.03M |